Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab.

Evangelou, Kyriacos; Rozani, Sofia; Tsagkaris, Christos

Evangelou, Kyriacos; Rozani, Sofia; Tsagkaris, Christos.

Evangelou K; Department of Medicine, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Rozani S; Department of Medicine, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Tsagkaris C; Global Community Educational Foundation, Hebersham, New South Wales, Australia.

J Med Virol ; 94(5): 1794-1795, 2022 05.

Article in English | MEDLINE | ID: covidwho-1604751

Subject(s)

Antibodies, Monoclonal; COVID-19 Drug Treatment; Abciximab; Antibodies, Monoclonal/immunology; Antibodies, Monoclonal/therapeutic use; Blood Platelets; Humans; Platelet Aggregation Inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Antibodies, Monoclonal Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27573

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google